Marcel Trautmann

GDI Cancer Research Lab / Div. of Translational Pathology @UK_Muenster
#sarcoma #cancerresearch #myxoidliposarcoma #synovialsarcoma

[Marcel Trautmann @trautma_m]

@biorxiv_cancer @Sarkomstiftung @DKFZ @NCT_HD @UK_Muenster 🚨Finally out in @CCR_AACR spearheaded by fantastic Lorena Heinst. Please check it out: https://t.co/0cOo934B1a

[Marcel Trautmann @trautma_m]

🔥 Happy to share our latest @biorxiv_cancer, exploring WEE1 mediated replication stress tolerance as vulnerability in FUS::DDIT3 driven #myxoidliposarcoma.

Great team effort - Thanks! @Sarkomstiftung @DKFZ @NCT_HD @UK_Muenster

Please check it out👇
https://t.co/paKn5MLiVa

[Ben Westphalen @BenWestphalen]

Critical topic addressed in @JCOPO_ASCO ⬇️

With ever more agents targeting fusion events in #cancer - how do we detect them properly 🤔

Answer provided: NGS with DNA/RNA analyses…

#OpenAccess #PrecisionMedicine @OncoAlert 🚨

https://t.co/FXvzVjzDhD

[Christian Thomas @thomachr87]

Always thought #Nanopore sequencing from #FFPE is impossible? Explore our paper: https://t.co/8KuCZxvRYw. Methylation & CNV profiling of CNS tumors. Great collaboration with @ulrichschueller and @LschweizerLeo. @nanopore

[Paul Huang Lab @HuangLabICR]

Our new paper "The Proteomic Landscape of Soft Tissue Sarcomas" is out in @NatureComms!
https://t.co/Hn1NODQ6jG

We characterise the proteomic profiles of >300 #sarcomas across 11 histological subtypes in paediatric & adult patients.

What did we learn from this study? A 🧵1/n

[Isidro Cortes-Ciriano @isidrolauscher]

On #NFAwarenessDay, heading to beautiful Vienna to present our genomics, tumour evolution and liquid biopsy work on #MPNST at #EuSARC2023 @eu_sarc @StAnna_CCRI. For a preview, check out @CD_AACR https://t.co/HBSe8pPKSz Thanks to @TomazouLab and the other organizers!

[Marcel Trautmann @trautma_m]

Our latest now online @MCR_AACR – please read!

Interdependence of SS18-SSX-driven #YAP1 and β-catenin-activation in #synovialsarcoma

https://t.co/d4vygCMdtY

Congrats to Ilka Isfort @UK_Muenster @WWU_Muenster

Thanks for great support #sarcoma research #DFG

[Marcel Trautmann @trautma_m]

Great collaborative effort now out in Nature @LeukemiaJnl, please read: Molecular profiling of EBV associated diffuse large B-cell #lymphoma. @FabianFrontzek

https://t.co/KkGCYWRkHw

[Marcel Trautmann @trautma_m]

@Sarcoma_papers @juandiaz_martin I very much enjoyed this review by @juandiaz_martin et al on genetic alterations and deregulation of hippo YAP/TAZ pathway in bone and soft tissue #sarcoma PMID: 36551696 recommended read!

[Dmitri Petrov @PetrovADmitri]

To the biology tweeps: To finish off 2022, @OdedRechavi and I thought it would be fun to hear from you about one paper from 2022 that you think we should all read. One paper per person. A few words why you think is important would be great too.

[Marcel Trautmann @trautma_m]

Online ahead of print @AJSPjournal, please read: Recurrent EWSR1::COLCA2 Fusions Define a Novel #sarcoma With Spindle/Round Cell Morphology and Strong Predilection for the Sinonasal Tract. Great effort by Abbas Agaimy & Co. @Sarkomstiftung
https://t.co/g7Yoy0SNsQ

[Stefan Fröhling @StefanFrohling]

Comprehensive molecular profiling to inform clinical decision making in #AYA #sarcomas is feasible in a European setting. Great team effort under the auspices of @EORTC, led by Marie Morfouace, Martin McCabe, @NCT_HD, @TMO_Heidelberg & @DKFZ.
https://t.co/9D3B2AVPSY

[Linda 👩‍🔬🦠 wears a mask 🦠 @linda_brunotte]

Our new study led by amazing Aileen Faist #WWU_Muenster #UK_Muenster and Sebastian Schloer is now online! Two pre-evaluated p38 inhibitors reduce the cytokine burden during COVID19...and so much more🤯. Check it out! https://t.co/Aa99ByepvK

[Stefan Fröhling @StefanFrohling]

Important results from the #MASTER precision oncology study: ~10% of adult cancer patients carry (likely) pathogenic germline variants, making a strong case for moving away from tumor-only sequencing to optimally inform clinical management. @DKFZ @NCT_HD @NCT_UCC_DD @DKTK_

[Ben Westphalen @BenWestphalen]

#PrecisionOncology is impossible w/o working in interdisciplinary teams & the core partner is #pathology 🤝

Looking very much forward to attending/speaking at this years @ESP_Pathology @esp_congress in Basel.

Reach out if you wanna catch up!

@OncoAlert 🚨#PrecisionMedicine

[Stefan Fröhling @StefanFrohling]

Please read our new paper on the clinical value of comprehensive cancer predisposition testing in the MASTER precision oncology trial. Another fantastic team effort of @NCT_HD, @NCT_UCC_DD, @DKFZ, and @DKTK_.
https://t.co/1IPMDpSqCl

[Stefan Fröhling @StefanFrohling]

Please read our new paper on the clinical value of comprehensive molecular profiling in patients with cancer of unknown primary site. Another wonderful team effort of the @NCT_HD, @NCT_UCC_DD, @DKFZ, and @DKTK_ MASTER precision oncology network. https://t.co/yJrpZb3JHK

[Anton Henssen @anton_gh]

Very happy to share this new publication from our lab, led by @HeathcliffDora1 , where we describe that preclinical models of alveolar rhabdomysarcoma are exceptionally sensitive to pharmacological ATR inhibition 🔥🔥👇🏻👇🏻 @NatureComms #1
https://t.co/9gC5YRaSVp

[Marcel Trautmann @trautma_m]

@schoffski Congrats @AgaWozniak1!👍